# Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

> **NCT04409041** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 43 (actual)

## Conditions studied

- Lichen Planopilaris
- Frontal Fibrosing Alopecia

## Interventions

- **DRUG:** Low-Dose Naltrexone

## Key facts

- **NCT ID:** NCT04409041
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04409041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04409041, "Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04409041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*